We would like to inform that you have received trial access to the new CAS BioFinder™ tool within CAS SciFinder. Trial access will begin October 15th and last until December 31st, 2025. A special introductory session will precede the tool's launch.
The introductory session, "CAS BioFinder™ – A new way to explore biological data," requires registration and will be conducted in English on the MS Teams platform. The meeting will be held on two dates:
CAS BioFinder™ centralizes and connects drug discovery-relevant information, providing you with actionable insights to accelerate lead optimization and bring life-changing drugs to patients faster. CAS BioFinder™ provides easy access to harmonized, normalized, bioactivity data curated and indexed from scientific literature, patents and journals to accelerate identifying key associations and optimizing compounds. The data foundation of CAS BioFinder™ allows you to visually explore relationships between modalities, diseases, protein targets, and biomarkers, helping empower your research process. Beyond published data, CAS BioFinder™ is able to generate predicted activity data for novel compounds to help you anticipate interactions for more confident lead selection and optimization.
For more information about the capabilities of the CAS BioFinder™ tool, please visit the website.